<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>ALA QUIN- hydrocortisone and clioquinolÂ creamÂ </strong><br>Crown Laboratories<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>Ala Quin, 0.5% Hydrocortisone and 3% Iodochlorhydroxyquin Cream</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Lc14dc485-081c-4c8f-953b-98a43b19a6bf"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Iodochlorhydroxyquin (Clioquinol) is an antifungal agent and a member of a family of drugs called hydroxyquinolines. Chemically, Iodochlorhydroxyquin is 5-chloro-7-iodo-quinolin-8-ol. Its structural formula is:</p>
<p><img alt="clioquinol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2ae30c6-ad64-47ed-b371-778eaebeeddf&amp;name=clioquinol%20structure.jpg"></p>
<p></p>
<p></p>
<p>The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Hydrocortisone is a member of this class. Chemically hydrocortisone is pregn-4-ene-3, 20-dione, 11, 17, 21-trihydroxy, (11Î²)-. Its structural formula is:</p>
<p><img alt="hydrocortisone" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2ae30c6-ad64-47ed-b371-778eaebeeddf&amp;name=hc%20structure.jpg"></p>
<p></p>
<p></p>
<p>Each gram of ALA-QUIN 
  <span class="Sup">Â®</span> contains 5 mg Hydrocortisone USP and 30 mg Iodochlorhydroxyquin USP in a cream base consisting of purified water, cetyl alcohol, glycerin, stearyl alcohol, polysorbate 80, sodium lauryl sulfate, cetyl palmitate, sorbic acid.
 </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Iodochlorhydroxyquin is a broad-spectrum antibacterial and antifungal. Its precise mechanism of action isÂ unknown. Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanismÂ of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, includingÂ vasoconstrictor assays, are used to compare and predict potencies that a recognizable correlation exists betweenÂ vasoconstrictor potency and therapeutic efficacy in man.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Lb148cb3c-f8bf-4a76-a214-39821134730d"></a><a name="section-3"></a><p></p>
<h1>Pharmacokinetics</h1>
<p class="First">The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.</p>
<p><br>
Topical corticosteroids can be absorbed from normal intact skin. <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of the topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See 
  <a href="#Lff086e51-b5a5-4859-a635-cc6f675755ce"> DOSAGE AND ADMINISTRATION</a>).
 </p>
<p><br>
Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
 </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="L380808dc-c443-422a-bcda-c134c5194566"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Based on a review of this drug by the National Academy of Sciences-National Research Council and/or otherÂ information, FDA has classified the indications as follows:</p>
<p>â€œPossiblyâ€? effective: Contact or <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>; impetiginized <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>; nummular <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>; infantile <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>;Â endogenous chronic infectious <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>; <span class="product-label-link" type="condition" conceptid="4148876" conceptname="Stasis dermatitis">stasis dermatitis</span>; <span class="product-label-link" type="condition" conceptid="133547" conceptname="Pyoderma">pyoderma</span>; nuchal <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span> and chronic eczematoid otitisÂ externa; <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> urticata; localized or disseminated <span class="product-label-link" type="condition" conceptid="4148920" conceptname="Neurodermatitis">neurodermatitis</span>; lichen simplex chronicus; anogenital pruritusÂ (vulvae, scroti, ani); <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>; bacterial dermatoses; mycotic dermatoses such as <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> (capitis, cruris, corporis,Â pedis); <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>; intertrigo.</p>
<p>Final classification of the less-than-effective indications requires further investigation.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Ld3845f65-7034-4cdc-95c3-88ffc32d18b4"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to lodochlorhydroxyquin-Hydrocortisone, or any of its ingredients or related compounds: lesionsÂ of the eye, <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> of the skin; most viral <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span> (including herpes simplex, <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>).</p>
<p>Patients sensitive to chloroxine, iodine, or iodine-containing preparations may also be sensitive to this medication.</p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="L7325b45b-d1a0-4a31-8a8d-040ba5fd75a9"></a><a name="section-6"></a><p></p>
<h1>Precautions</h1>
<p class="First"><span class="Italics">General</span></p>
<p>Staining of skin and fabrics may occur. Additionally, there are rare reports of discoloration (yellowing) of hair andÂ nails. Iodochlorhydroxyquin- Hydrocortisone may prove irritating to sensitized skin in rare cases. If irritation occurs,Â discontinue therapy. Check with physician if no improvement within 1 to 2 weeks.</p>
<p>Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA)Â axis suppression, manifestations of Cushingâ€™s syndrome, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and glucosuria in some patients. SignsÂ and symptoms of systemic toxicity, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, or adrenal suppression have not been reported withÂ Iodochlorhydroxyquin-Hydrocortisone. Nevertheless, the possibility of suppression of the HPA axis during therapyÂ should be kept in mind, especially when the drug is used under occlusive dressings, for a prolonged period, or forÂ treating extensive cutaneous areas since significant absorption of corticosteroid may occur under these conditions,Â particularly in children and infants.</p>
<p>Patients receiving a large dose of a potent topical corticosteroid applied to a large surface area or under anÂ occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary freeÂ cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw theÂ drug, to reduce the frequency of application, or to substitute a less potent corticosteroid.</p>
<p>Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug.Â Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemicÂ corticosteroids.</p>
<p>Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible toÂ systemic toxicity (See 
       
 
  <a href="#Lb52dad25-6901-4559-a6c1-9324cba418b0">PRECAUTIONS â€“ Pediatric Use</a>)
      

 </p>
<p>If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.</p>
<p>Iodochlorhydroxyquin may be absorbed through the skin and interfere with <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">thyroid function test</span>.</p>
<p>Iodochlorhydroxyquin may cause significant elevation of protein-bound iodine (PBI) or butanol-extractable iodineÂ (BEI) and a decrease in radioactive iodine (RAI) uptake. If such tests are contemplated, wait at least one monthÂ between discontinuation of therapy and performance of these tests.</p>
<p>Prolonged use may result in overgrowth of nonsusceptible organisms requiring appropriate therapy. In theÂ presence of systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, appropriate systemic antibiotics should be used.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="L04ac7b00-baea-4252-8321-0db74a315405"></a><a name="section-7"></a><p></p>
<h1>Information for the Patient</h1>
<p class="First">Patients using Iodochlorhydroxyquin-Hydrocortisone should receive the following information and instructions:</p>
<p>1. This medication is to be used as directed by the physician.</p>
<p>2. This medication is for external use only. Do not use in or around the eyes.Â 
       This product is not for ophthalmic use.</p>
<p>3. Patients should be advised not to use this medication for any disorder other than for which it is prescribed.</p>
<p>4. Patients should report any signs of local adverse reactions especially under occlusive dressing.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="L8455c197-5f1d-4cd4-a4f6-8fdb3fd476a1"></a><a name="section-8"></a><p></p>
<h1>Latoratory Tests</h1>
<p class="First">The following tests may be helpful in evaluating the HPA axis suppression:</p>
<p>âˆ™ Urinary free cortisol test</p>
<p>âˆ™ ACTH stimulation test</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="Le6def516-2637-4e99-a364-57416e0f2bd5"></a><a name="section-9"></a><p></p>
<h1>Carcinogenesis, Mutagenesis, and Impairment of Fertility</h1>
<p class="First">Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.
       
 
  <br>Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.
      

 </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Leed4c1e7-d614-4631-9419-f306ac07127a"></a><a name="section-10"></a><p></p>
<h1>Pregnancy Category C</h1>
<p class="First">Although topical steroids have not been reported to have an adverse effect on pregnancy, the safety of their useÂ in pregnant women has not been absolutely established. Use of large amounts or for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of timeÂ is not recommended since systemic absorption may occur. In laboratory animals, increases in incidence of fetalÂ abnormalities have been associated with exposure of gestating females to topical corticosteroids, in some casesÂ at rather low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermalÂ application in laboratory animals. There are no adequate and well-controlled studies in pregnant women onÂ teratogenic effects from topical applied corticosteroids. Topical corticosteroids should be used during pregnancyÂ only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Therefore, drugs of this class should not be used extensively on pregnant patients in large amounts or forÂ <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of time.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Lf031facf-2ef9-4f61-a0fe-0c6bb5d9ddfc"></a><a name="section-11"></a><p></p>
<h1>Nursing Mothers</h1>
<p class="First">It is not known whether topical administration of this drug could result in sufficient systemic absorption toÂ produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breastÂ milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercisedÂ when this class of drug is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Lb52dad25-6901-4559-a6c1-9324cba418b0"></a><a name="section-12"></a><p></p>
<h1>Pediatric Use</h1>
<p class="First">Use is not recommended for infants or children up to 2 years of age.</p>
<p>Iodochlorhydroxyquin may produce false-positive ferric chloride test results for <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">phenylketonuria</span> (PKU) ifÂ iodochlorhydroxyquin is present in the neonateâ€™s diaper or urine.</p>
<p>Special care must be exercised in using this drug in a pediatric patient. It is recommended that only low-potencyÂ topical corticosteroids that are not fluorinated and that have a free 17-hydroxyl group be used in children unlessÂ there is a very specific indication for one or the other topical corticosteroids.Â </p>
<p>As a general rule, pediatric therapy continuing for longer than 2 weeks and consisting of doses in excess ofÂ 2 daily applications (with low-potency corticosteroids) should be carefully evaluated by the physician. This isÂ especially important if medication is applied to more than 5-10% of the body surface or if an occlusive dressing isÂ used. A tight-fitting diaper or one covered with plastic pants may constitute an occlusive dressing.</p>
<p>Administration of topical corticosteroids to children should be limited to the least amount compatible with anÂ effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development ofÂ children.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Lea87dc34-ccf5-4560-a11d-dc249d0da1a9"></a><a name="section-13"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">There have been a few reports of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> as well as thinning of the skin with easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>.</p>
<p>The following local adverse reactions have also been reported with topical corticosteroids and iodochlorhydroxyquinÂ especially under occlusive dressings; burning; <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>; irritation; dryness; <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>; <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>,Â <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>; <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>; <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">acneiform eruptions</span>; hypopigmentation; <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">perioral dermatitis</span>; allergic contactÂ <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>; maceration of the skin, <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span>; <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span>; <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>; <span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">miliaria</span> or other signs of irritation notÂ present before therapy.</p>
<p>Discontinue therapy if any untoward reaction occurs.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Lff086e51-b5a5-4859-a635-cc6f675755ce"></a><a name="section-14"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Apply a thin layer to the affected area 2 to 4 times daily or as directed by a physician.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="Lc3eb9ac0-4df6-4662-82ca-4e3c06c83429"></a><a name="section-15"></a><p></p>
<h1>PACKAGING AND STORAGE</h1>
<p class="First">Store at room temperature 15
  <span class="Sup">o</span> - 30
  <span class="Sup">o</span>C (59
  <span class="Sup">o</span> - 86
  <span class="Sup">o</span>F) in original container.
 </p>
<p>Protect from freezing.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="L8d5ab0af-4f33-4429-bb9e-331ec49860f6"></a><a name="section-16"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ALA-QUIN (Hydrocortisone USP, 0.5% and Iodochlorhydroxyquin USP, 3%) Cream is supplied in</p>
<p>1 ounce tube Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NDC 0316-0123-01
       
 
  <br>2 ounce (two 1oz tubes) Â Â Â Â Â Â NDC 0316-0123-56
      

 </p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Revised: Sept. 2015</span></p>
<p>Manufactured and Distributed by:Â Crown Laboratories, Inc.,Â Johnson City, Tennessee 37604</p>
<p>PRINTED IN USA</p>
<p>P8000.03</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="id_link_211df6cc-00ec-56f0-e054-00144ff88e88"></a><a name="section-17"></a><p></p>
<h1>ALA-Quin 1oz Label</h1>
<p class="First"><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">NDC 0316-0123-01</span></p>
<p>ALA-QUIN 
  <span class="Sup">Â®</span></p>
<p>HYDROCORTISONE 0.5%</p>
<p>IODOCHLORHYDROXYQUIN 3% CREAM</p>
<p>1 OZ (28.4 g)</p>
<p><span class="Bold">For External Use Only. Not for Ophthalmic Use.</span><br><br><span class="Bold">Keep Out Of Reach Of Children.</span></p>
<p>See crimp of tube for Expiration Date and Batch Number</p>
<p>Each gram contains 5 mg Hydrocortisone USP and 30 mg Iodochlorhydroxyquin USP in a cream base consisting of purified water, cetyl alcohol, glycerin, stearyl alcohol, polysorbate 80, sodium lauryl sulfate, cetyl palmitate, sorbic acid.</p>
<p><span class="Bold">Usual Dosage:</span> Apply as a thin film to the affected areas 2 to 4 times daily. See insert for full prescribing information.
 </p>
<p>Store at room temperature 15
  <span class="Sup">o</span>-30
  <span class="Sup">o</span>C (59
  <span class="Sup">o</span>-86
  <span class="Sup">o</span>F). Protect from freezing.
 </p>
<p>Manufactured and Distributed by:</p>
<p>Crown Laboratories, Inc.</p>
<p>Johnson City, TN 37604</p>
<p>P6501.02</p>
<p></p>
<p><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2ae30c6-ad64-47ed-b371-778eaebeeddf&amp;name=P650102alaquin1ozlabel.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="L0f3161db-9ef6-446a-80d7-8965fd7591fe"></a><a name="section-18"></a><p></p>
<h1>ALA-QUIN 1oz Carton</h1>
<p class="First"><span class="Bold">NDC 0316-0123-01</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p>ALA-QUIN 
  <span class="Sup">Â®</span></p>
<p>HYDROCORTISONE 0.5%</p>
<p>IODOCHLORHYDROXYQUIN 3% CREAM</p>
<p>1 OZ (28.4 g)</p>
<p>Each gram contains 5 mg Hydrocortisone USP and 30 mg Iodochlorhydroxyquin USP in a cream base consisting of purified water, cetyl alcohol, glycerin, stearyl alcohol, polysorbate 80, sodium lauryl sulfate, cetyl palmitate, sorbic acid.</p>
<p>ï»¿Directions for puncturing tube seal: Remove cap. Reverse cap and place puncture tip onto seal; push down until seal is punctured. Screw cap back on to close.</p>
<p><span class="Bold">Directions for use:</span> Apply as a thin film to the affected areas 2 to 4 times daily or as directed by a physician.
 </p>
<p><span class="Bold">Refer to package insert for full prescribing information.</span></p>
<p><span class="Bold">FOR EXTERNAL USE ONLY. </span></p>
<p><span class="Bold">NOT FOR OPHTHALMIC USE.</span></p>
<p><span class="Bold">KEEP OUT OF THE REACH OF CHILDREN.</span></p>
<p>Store at room temperature 15
  <span class="Sup">o</span>-30
  <span class="Sup">o</span>C (59
  <span class="Sup">o</span>-86
  <span class="Sup">o</span>F). Protect from freezing.
 </p>
<p>See end of carton for Expiration Date and Batch Number.</p>
<p>Manufactured and Distributed by:</p>
<p>Crown Laboratories, Inc.</p>
<p>Johnson City, TN 37604</p>
<p>P9003.00</p>
<p><img alt="carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2ae30c6-ad64-47ed-b371-778eaebeeddf&amp;name=P900300alaquin1ozcarton.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALA QUINÂ 		
					</strong><br><span class="contentTableReg">hydrocortisone and iodochlorhydroxyquin cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0316-0123</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCORTISONE</strong> (HYDROCORTISONE) </td>
<td class="formItem">HYDROCORTISONE</td>
<td class="formItem">5Â mg Â inÂ 1Â g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CLIOQUINOL</strong> (CLIOQUINOL) </td>
<td class="formItem">CLIOQUINOL</td>
<td class="formItem">30Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CETYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CETYL PALMITATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0316-0123-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">28.4 g in 1 TUBE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0316-0123-56</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">28.4 g in 1 TUBE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">08/19/1970</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Crown Laboratories
							(079035945)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Crown Laboratories (079035945)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Crown Laboratories</td>
<td class="formItem"></td>
<td class="formItem">079035945</td>
<td class="formItem">manufacture(0316-0123)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>210d6f10-0fea-4f7e-e054-00144ff8d46c</div>
<div>Set id: d2ae30c6-ad64-47ed-b371-778eaebeeddf</div>
<div>Version: 1</div>
<div>Effective Time: 20151002</div>
</div>
</div>Â <div class="DistributorName">Crown Laboratories</div></p>
</body></html>
